| 000 | 01651 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250514164521.0 | ||
| 264 | 0 | _c20040621 | |
| 008 | 200406s 0 0 eng d | ||
| 022 | _a1042-8194 | ||
| 024 | 7 |
_a10.1080/1042819031000116706 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTsimberidou, Apostolia M | |
| 245 | 0 | 0 |
_aAnti-B4 blocked ricin post chemotherapy in patients with chronic lymphocytic leukemia--long-term follow-up of a monoclonal antibody-based approach to residual disease. _h[electronic resource] |
| 260 |
_bLeukemia & lymphoma _cOct 2003 |
||
| 300 |
_a1719-25 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _ximmunology |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoconjugates _ximmunology |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 |
_aLeukemia, Lymphocytic, Chronic, B-Cell _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasm, Residual _xdrug therapy |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aRemission Induction |
| 650 | 0 | 4 |
_aRicin _ximmunology |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aGiles, Francis J | |
| 700 | 1 | _aKantarjian, Hagop M | |
| 700 | 1 | _aKeating, Michael J | |
| 700 | 1 | _aO'Brien, Susan M | |
| 773 | 0 |
_tLeukemia & lymphoma _gvol. 44 _gno. 10 _gp. 1719-25 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1080/1042819031000116706 _zAvailable from publisher's website |
| 999 |
_c14423467 _d14423467 |
||